Apple (NASDAQ AAPL) introduced a new line of product on Monday. The Cupertino based technology company came up with the Apple Watch product which is the newest product in the wearable technology segment. Amid much speculation and expectancy, Apple showed the features and specifications of the product, along with the price range. Despite the let…
Apple (NASDAQ AAPL) officially unveiled its Apple Watch product on Monday in an event which showcased all the features of the much anticipated product. Apple have been quite upbeat about the product and the market had been eagerly waiting for the product. Many were expecting this product to change the landscape of the wearable technology…
Myriad Genetics (NASDAQ:MYGN) is lower after the molecular diagnostic company disclosed in a regulatory filing Tuesday that the U.S. District Court for the District of Utah has denied the company’s motion for preliminary injunctive relief against Ambry Genetics’s sale of certain testing services that MYGN believes infringes on its patents. Shares are down 9.80% at…
ReneSola Ltd. (ADR)(NYSE:SOL) on Mar. 5 announced it has delivered approximately 45,900 of its high-efficiency modules to the Photovoltaic Plant of Ferrara Aranova project, a 11.7MW ground-mounted solar project in Italy developed by Tozzi Sud S.p.A., an Italian designer, manufacturer, and installer of power plants. ReneSola Ltd. (ADR) (NYSE:SOL) stock performance was -5.23% in last…
Agios Pharmaceuticals (NASDAQ:AGIO) was downgraded by Zacks from a “neutral” rating to an “underperform” rating in a research report issued to clients and investors on Monday, Analyst Ratings News reports. Agios Pharmaceuticals Inc (NASDAQ:AGIO) stock performance was 2.84% in last session and finished the day at $46.74. Traded volume was 983,271 million shares in the…
German health regulators have granted Northwest Biotherapeutics Inc (NASDAQ:NWBO) special permission to sell its experimental brain cancer drug, DCVax-L, in the country, even though the small US biotechnology company has not yet completed its late-stage trial of the immunotherapy. Northwest Biotherapeutics, Inc (NASDAQ:NWBO) stock performance was 29.55% in last session and finished the day at…
